Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study

Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients

(2020) Anne-Geneviève Marcelin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical targeting of HIV capsid protein with a long-acting small molecule

(2020) John O. Link et al.   NATURE

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

(2020) Nicolas Margot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

(2011) Nicolas A. Margot et al.   ANTIVIRAL RESEARCH

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat

(2010) N. A. Margot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY